<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115518</url>
  </required_header>
  <id_info>
    <org_study_id>NEAR L-284/2004</org_study_id>
    <nct_id>NCT00115518</nct_id>
  </id_info>
  <brief_title>Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Locoregional Radiotherapy in Combination With Cetuximab in Inoperable Non-Small Cell Lung Cancer Stage III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study combined locoregional radiotherapy with cetuximab in
      non-operable NSCLC Stage III (Phase II trial).

      Endpoints:

      safety and feasibility (primary) response, survival, time to progression (secondary)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study entry examinations:

        -  blood cell count

        -  liver enzymes

        -  ventilatory function test

        -  pregnancy test (premenopausal women)

        -  CT of the thorax

        -  CT of the brain

        -  Ultrasound of the liver

        -  Bone scan

        -  FDG PET scan (after inclusion)

      Follow-up examinations (2 months, than every 3 months):

        -  patients history and examination

        -  CT scan of the thorax

        -  ventilatory functions test

        -  FDG PET scan (at least at 6 months)

        -  bone scan (yearly)

        -  ultrasound of the liver (every 6 months)

      Cetuximab administration:

        -  450 mg / m^2 body surface on week 1

        -  250 mg /m^2 body surface weekly, week 2 -21

      Radiation therapy:

        -  intensity modulated radiation therapy of primary tumor and mediastinum (2 Gy single
           dose, total dose 50 Gy; 5 fractions per week) with boost to the PET positive sites (2 Gy
           single doses up to 66 Gy). Radiation therapy during weeks 2-8.

      Amendment 1/07: 3D conformal RT possible, but not if FeV1 &lt; 1.5L of &lt; 50%
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety: rate of side effects (skin reactions, allergic reactions, decrease of pulmonary function)</measure>
    <time_frame>3 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response (RECIST criteria of primary tumor and enlarged lymphnodes)</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival (at 3 years)</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression (locally and systemically)</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified NSCLC

          -  Not eligible for Radiochemotherapy or patient refuses chemotherapy

          -  FeV1 &gt;1.5 L or min. 50%

          -  KPI &gt;= 70%

          -  Life expectancy &gt; 6 months

          -  Weight loss less than 10% of body weight in 12 months

          -  Compliance

          -  Adequate blood counts (LC &gt; 3000 x 10^3/ml, Tc &gt;100000 x 10^3/ml, Hb &gt; 10 g/dl)

          -  Effective contraception

        Amendment 1/07: FeV1 &gt;1.2 L or min 40%

        Exclusion Criteria:

          -  Active infection

          -  Reduced liver function

          -  Vena cava superior syndrome

          -  Malignant pleural effusion

          -  Pregnancy or breast feeding

          -  Additional serious systemic disease

          -  Secondary malignancy (except carcinoma in situ of the cervix, basalioma of the skin,
             secondary cancer in remission for &gt; 5 years)

          -  Known allergies against proteins

          -  History of former antibody therapy

          -  Allergy against i.v. contrast agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus K Herfarth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Jensen AD, MÃ¼nter MW, Bischoff HG, Haselmann R, Haberkorn U, Huber PE, Thomas M, Debus J, Herfarth KK. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer. 2011 Jul 1;117(13):2986-94. doi: 10.1002/cncr.25888. Epub 2011 Jan 24.</citation>
    <PMID>21264838</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2005</study_first_submitted>
  <study_first_submitted_qc>June 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2005</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Klaus Herfarth, MD</name_title>
    <organization>UJniversity of Heidelberg</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

